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Abstract
Both nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) play 
important roles in metabolomics. The complementary features of NMR and MS make their 
combination very attractive; however, currently the vast majority of metabolomics studies use 
either NMR or MS separately, and variable selection that combines NMR and MS for biomarker 
identification and statistical modeling is still not well developed. In this study focused on 
methodology, we developed a backward variable elimination partial least-squares discriminant 
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analysis algorithm embedded with Monte Carlo cross validation (MCCV-BVE-PLSDA), to 
combine NMR and targeted liquid chromatography (LC)/MS data. Using the metabolomics 
analysis of serum for the detection of colorectal cancer (CRC) and polyps as an example, we 
demonstrate that variable selection is vitally important in combining NMR and MS data. The 
combined approach was better than using NMR or LC/MS data alone in providing significantly 
improved predictive accuracy in all the pairwise comparisons among CRC, polyps, and healthy 
controls. Using this approach, we selected a subset of metabolites responsible for the improved 
separation for each pairwise comparison, and we achieved a comprehensive profile of altered 
metabolite levels, including those in glycolysis, the TCA cycle, amino acid metabolism, and other 
pathways that were related to CRC and polyps. MCCV-BVE-PLSDA is straightforward, easy to 
implement, and highly useful for studying the contribution of each individual variable to 
multivariate statistical models. On the basis of these results, we recommend using an appropriate 
variable selection step, such as MCCV-BVE-PLSDA, when analyzing data from multiple 
analytical platforms to obtain improved statistical performance and a more accurate biological 
interpretation, especially for biomarker discovery. Importantly, the approach described here is 
relatively universal and can be easily expanded for combination with other analytical technologies.
Graphical abstract
Metabolomics provides an important approach in systems biology to investigate biological 
states as well as the effects of internal and external perturbations through the study of 
changes in metabolite concentrations and fluxes.1–9 Complex metabolic processes in living 
systems respond to many stimuli, including diseases and drugs, resulting in alterations in 
metabolic profiles; metabolomics aims to detect these changes at the molecular level using 
advanced analytical chemistry techniques and multivariate statistical analysis. Metabolomics 
studies have resulted in a number of important findings, including a deeper understanding of 
cancer metabolism10,11 and drug toxicity,12,13 the potential for improved early disease 
detection14–16 or therapy monitoring,4,17 and successful applications in environmental 
science,18 nutrition,19 etc.
The two most commonly used analytical technologies in metabolomics are nuclear magnetic 
resonance (NMR) spectroscopy and mass spectrometry (MS).20,21 NMR is well-known as a 
premier method for structural identification and for the analysis of multicomponent mixtures 
as it is rapid and nondestructive, requires little or no sample preparation, and provides highly 
reproducible (coefficients of variation, CVs, of a few percent) and quantitative results.22–25 
MS is another essential method for identifying and quantifying metabolites, especially those 
of low abundance in complex biosamples, because of its intrinsically high sensitivity and 
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high selectivity.26,27 Notably, metabolomics data from NMR and MS experiments are 
complex because they usually contain signals from many metabolites; therefore, multivariate 
statistical analysis plays an important role in metabolomics for reducing data dimensions, 
differentiating similar spectra, building predictive models, etc.28,29
NMR and MS generate different metabolic profiles from the same sample; thus, their 
combination can be very valuable in metabolomics. One thereby can obtain a more 
comprehensive profile of detectable metabolites, and as shown below, one can potentially 
improve the reliability and predictive accuracy of statistical models. However, currently the 
vast majority of metabolomics studies use either NMR or MS separately, although a growing 
number of studies do combine NMR and MS analysis to advantage.30–44 For example, we 
developed principal component (PC)-directed partial least-squares (PLS) analysis to 
combine one-dimensional (1D) 1H NMR and direct analysis in real time (DART) MS data to 
improve breast cancer detection.31 Powers and co-workers and Karaman et al. have proposed 
multiblock PLS approaches to integrate data from MS and NMR.43,44 Thus far, however, the 
potential benefits of combining NMR and MS for biomarker discovery and statistical 
modeling are still not well recognized. In particular, optimizing variable selection is one of 
the major challenges for multiblock data because of the extra number of variables. Variable 
selection is often performed using univariate analysis or as a byproduct of full-scale 
multivariate statistical analysis;32,43 the contribution of each individual variable to 
multivariate modeling is rarely studied. Therefore, it is highly desirable to further investigate 
and develop approaches in metabolomics to make better use of both NMR and MS data.
In this study focused on method development, we examined the performance of 
combining 1H NMR and targeted LC/MS/MS metabolite profiles from patients with 
colorectal cancer (CRC), patients with polyps, and healthy controls. It is important to 
improve CRC and polyp detection, as CRC is one of the most prevalent and deadly cancers 
in the United States and worldwide.45 To date, numerous metabolic alterations have been 
found in CRC tissue,37,46–48 serum,49–55 urine,56 and fecal water57 from the metabolite 
profiles measured by NMR and/or MS, and therefore, one might surmise that combining 
NMR and MS data could result in improved metabolite panels. Here, we analyzed a total of 
127 serum samples from three groups of subjects, and potential biomarkers were selected 
using a backward variable elimination58 approach that was incorporated into multiblock PLS 
discriminant analysis (BVE-PLSDA). Monte Carlo cross validation (MCCV)59,60 was 
performed and demonstrated the robust diagnostic power of this NMR-and MS-based 
metabolomics approach in differentiating healthy controls from patients with CRC and 
polyps.
EXPERIMENTAL PROCEDURES
Chemicals
Deuterium oxide (D2O, 99.9% D), L-tyrosine-13C2, and sodium L-lactate-13C3 were 
purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). 
Trimethylsilylpropionic-2,2,3,3-d4 acid sodium salt (TSP) was obtained from Sigma-Aldrich 
(Milwaukee, WI). Acetonitrile (LC/MS grade), ammonium acetate (LC/MS grade), 
methanol (LC/MS grade), and acetic acid (LC/MS grade) were all purchased from Fisher 
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Scientific (Pittsburgh, PA). Deionized (DI) water was provided in house by a Synergy 
Ultrapure Water System from EMD Millipore (Billerica, MA).
Serum Samples
All work was conducted in accordance with protocols approved by the Indiana University 
School of Medicine and Purdue University Institutional Review Boards. All subjects in the 
study provided informed consent according to institutional guidelines. Patients undergoing 
colonoscopy for CRC screening or CRC surgery were evaluated, and blood from the patients 
was obtained after overnight fasting and identical bowel preparation but prior to their 
procedure (colonoscopy or surgery). Healthy or polyp status was determined after screening. 
In total, blood samples from 28 CRC patients, 44 individuals with polyps, and 55 healthy 
controls were collected and analyzed by NMR and MS. The detailed demographic and 
clinical parameters for the patients and healthy controls included in this study are listed in 
Table 1. Each blood sample was allowed to clot for 45 min and then centrifuged at 2000 rpm 
for 10 min. Sera were collected, aliquoted into separate vials, transported under dry ice, and 
then stored at −80 °C until they were used.
1H NMR Spectroscopy
Five hundred thirty microliters of each serum sample was transferred into a 5 mm NMR 
tube. To minimize the interference of macromolecules with the TSP signal, a 60 μL TSP 
solution (20.9 nmol in D2O) sealed in a coaxial glass capillary that served as a chemical shift 
reference (δ 0.00) was placed in the NMR tube during the experiment. All 1H NMR 
experiments were performed at 25 °C on a Bruker DRX 500 MHz NMR spectrometer 
equipped with a TXI probe. 1H NMR data for each sample were acquired using the one-
dimensional CPMG (Carr–Purcell–Meiboom–Gill) pulse sequence with water presaturation. 
For each spectrum, 128 transients were collected and 16K data points were acquired using a 
spectral width of 6000 Hz. The data were Fourier transformed after an exponential 
weighting function corresponding to 0.5 Hz line broadening had been applied. The spectra 
were phased and baseline corrected using Bruker TopSpin software (version 3.5). The 
spectral data were deposited into The Metabolomics Consortium Data Repository and 
Coordinating Center (DRCC, Study ST000285).61 We performed manual metabolite 
identification and peak integration (based on characteristic chemical shift and multiplicity). 
Table S1 shows the list of metabolites detected by NMR and their chemical shift regions 
used for peak integration.23,24
LC/MS/MS
A robust targeted LC/MS/MS method has recently been developed and used in a number of 
studies in the Northwest Metabolomics Research Center (NW-MRC).11,15,53,62–67 In this 
study, the MS data from the same samples as those measured by NMR, collected in our 
previous study,15 were used to demonstrate the performance of the NMR–MS combination. 
Briefly, the LC/MS/MS experiments were performed on an Agilent 1260 LC (Agilent 
Technologies, Santa Clara, CA) AB Sciex QTrap 5500 MS (AB Sciex, Toronto, ON) system. 
Table S2 shows the LC gradient conditions. We monitored 99 and 59 MRM transitions in 
negative and positive mode, respectively (158 transitions in total). The optimized MS 
conditions are listed in Table S3. The extracted MRM peaks were integrated using 
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MultiQuant version 2.1 (AB Sciex). The LC/MS/MS data were also deposited into the 
DRCC (Study ST000284).61
Data Analysis
A TSP solution of known concentration contained in a separate glass capillary was used to 
provide a chemical shift reference and to normalize the NMR data. In this study, we used the 
same MS data that have been investigated in a previous study;15 however, here we analyzed 
the samples that were measured by both NMR and MS. In the published study,15 we 
observed that normalization using the QC data on a metabolite-by-metabolite basis reduced 
technical variation in the data. For example, we obtained a median QC CV of 8%, ranging 
from 5 to 31% with ~80% metabolites having a CV of <15% after QC normalization. Both 
NMR and MS data were autoscaled prior to multivariate statistical analysis.
Figure 1 shows the flowchart of MCCV-BVE-PLSDA, describing the process of identifying 
a mixed panel of NMR and MS markers to improve CRC and polyp detection. We compared 
the performance of NMR and MS data, both individually and in combination (NMR–MS). 
On the basis of the concept of BVE,58 we developed a MCCV-BVE-PLSDA algorithm to 
obtain the variable subset that generated improved prediction. The analysis started by 
including all metabolite signals (variables) and stopped once every variable had been 
examined. In each iteration, one variable (metabolite) was removed, and the remaining 
variables were used for PLS-DA. The variables with the highest prediction accuracy for the 
test samples in MCCV59,60 were kept for the next iteration. During MCCV (which was 
repeated 500 times for each variable), all samples were randomly divided into two sets, 70% 
as the training set and 30% as the test set. PLS-DA was performed on the training set, and 
then the resulting model was used to predict the classification of test set samples. The 
sample membership could be either correctly assigned, termed true class, or randomly 
assigned (permutation). Several metrics were used to estimate and compare the performance 
of the models. First, classification accuracy was used to measure the performance; for 
example, if 1 was assigned as the dummy index for the CRC group and 0 was used for the 
control group, 0.5 would be used as the threshold to determine the classification for both the 
training and test samples. Classification accuracy was calculated as the ratio between the 
number of correctly predicted samples and the total number of samples, which takes both 
false positives and false negatives into consideration. In addition, the area under the receiver 
operator characteristics curve (AUROC) was also used as a performance metric.
All analyses were conducted in Matlab (R2008a, Mathworks, Natick, MA) installed with the 
PLS Toolbox (version 4.11, Eigenvector Research, Inc., Wenatchee, WA) using scripts 
written in house.
RESULTS AND DISCUSSION
1H NMR and MS Spectra
Figure S1a shows a typical 500 MHz 1D 1H NMR spectrum of a serum sample from a colon 
cancer patient. The spectrum contained NMR signals from small molecules, including 
formate, phenylalanine, tyrosine, histidine, glucose, lactate, creatinine, glutamine, alanine, 
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valine, isoleucine, leucine, etc. In total, 70 metabolite variables (Table S1) were obtained 
from the 1H NMR spectra by manual peak integration.
The targeted LC/MS/MS system allowed the detection of 158 (including two 13C-labeled 
internal standards) MRM transitions (Table S3), for the metabolites from more than 20 
different metabolite classes (e.g., amino acids, carboxylic acids, pyridines, etc.) and from 
>25 important metabolic pathways (e.g., TCA cycle, amino acid metabolism, glycolysis, 
etc.). Panels b and c of Figure S1 show the overlapped extracted ion chromatograms (EICs) 
of the metabolites that were detected in the serum sample from a colon cancer patient with 
positive and negative ionization, respectively. In total, we detected 113 metabolites that were 
present in the serum samples, and they are highlighted in the ID column of Table S3.
It can be clearly seen that NMR and MS metabolic profiles have some overlap (Tables S1 
and S3), such as lactate and glucose that were detected on both instruments. Meanwhile, 
many metabolites were detected only on one platform or the other; for example, citrate could 
be detected by only NMR, and reduced glutathione was measured by LC/MS/MS alone. In 
Figure 2a, we show the correlation between all the NMR and MS variables, while Figure 2b 
presents the correlation between the subset of metabolites that can be detected by both NMR 
and MS. Many metabolites had low correlation values between NMR and MS in Figure 2a; 
however, most of the overlapped metabolites had large correlation coefficients (Figure 2b). 
Nevertheless, a few metabolites in Figure 2b had weak correlations, which are probably in 
part due to the presence of matrix effects in the MS data or peak overlap in the NMR 
spectra.
CRC versus Healthy Controls
Panels a and b of Figure 3 show the results of MCCV-BVE-PLSDA in selecting a subset of 
metabolite markers for differentiating CRC patients from healthy controls, using NMR, MS, 
and NMR–MS data. As shown in Figure 3a, the highest classification accuracy of the NMR–
MS data was clearly better than that using the models derived from either NMR or MS 
alone. As could be anticipated, an excessive number of variables led to the deterioration of 
statistical models, and there was a number and/or range of variables that could produce the 
best statistical performance. This was consistently observed for all the NMR-, MS-, and 
NMR–MS-based models.
Table 2 summarizes the selected sets of metabolites resulting from MCCV-BVE-PLSDA and 
their statistical performance in the pairwise comparisons among CRC, polyps, and healthy 
controls. In the case of CRC versus healthy controls, a set of seven NMR variables provided 
the best classification accuracy of 0.84 ± 0.07, compared to 0.71 ± 0.08 for all 70 variables. 
The MS data generated a classification accuracy of 0.93 ± 0.05 using 19 variables compared 
to a value of 0.80 ± 0.07 for all 113 variables. Interestingly, it was observed that simply 
putting the NMR and MS data together does not guarantee better statistical performance 
(0.79 ± 0.08 for all 183 variables), because too many poorly performing variables will 
reduce prediction accuracy. However, after MCCV-BVE-PLSDA using the combined set of 
NMR–MS data, the highest classification accuracy of 0.95 ± 0.05 was achieved using 31 
variables. The complementary information provided by NMR and MS was beneficial in 
improving the statistical analysis. Therefore, we recommend incorporating appropriate 
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variable selection in multivariate statistical analysis to minimize data redundancy, a step that 
is currently not often performed.
Figure 3b compares the classification accuracy of true class models and random 
permutations in MCCV, when the selected set of variables was used in MCCV-BVE-
PLSDA. As expected, the average classification accuracy of random permutations was very 
close to 0.5, regardless of whether NMR, MS, or NMR–MS data were used. The 
classification accuracy values of true class models were clearly higher than those of random 
permutations, which further confirmed that the NMR and/or MS variables did contain 
variations related to CRC.
Table S4 shows the alterations of selected metabolite markers by MCCV-BVE-PLSDA from 
the NMR and/or MS data that were involved in the comparison between CRC patients and 
healthy controls. The metabolite markers from the combined NMR–MS data had a 
significant overlap with those derived from the models based on NMR or MS data alone. It 
can be seen that both NMR (seven variables) and MS (24 variables) contributed to the mixed 
panel of biomarker candidates (NMR–MS). The important NMR and MS metabolites 
showed no overlap, with the exception of histidine (which decreased in CRC serum for both 
NMR and MS), providing the evidence that NMR and MS can make unique contributions to 
statistical modeling in metabolomics. The unpaired Student’s t test was also performed on 
each metabolite to assess its statistical significance between the two groups. In the NMR–
MS data, five NMR variables and nine MS variables had P values of <0.05. We also list the 
adjusted P values in Table S4, with the false discovery rate (FDR) controlled at 0.05.
CRC versus Polyps
Similarly, we examined this combined NMR–MS metabolomics approach to differentiate 
CRC from polyp patients. As shown in Figure S2a and Table 2, 11 NMR variables were 
required to obtain the highest classification accuracy of 0.83 ± 0.07 in MCCV-BVE-PLSDA, 
and 21 selected MS variables provided a classification accuracy of 0.95 ± 0.04. The 
combination of 30 NMR and MS variables from the NMR–MS data produced a significantly 
better classification accuracy of 0.98 ± 0.02. The NMR–MS combination was more efficient 
in improving CRC and polyp separation compared to NMR or MS alone. It was also seen in 
Figure S2a that more variables did not necessarily provide better statistical performance, for 
NMR, MS, or NMR–MS data. Again, the use of variable selection in the statistical analysis 
of metabolomics data is highly effective in improving the modeling.
The results of MCCV for the selected variables from each data set showed that the average 
classification accuracy of random permutations (~0.5) was clearly lower than that of the true 
class models (Figure S2b). This result again indicated that the NMR and/or MS variables 
extracted a high degree of the biological variation related to CRC or polyps. From Table S5, 
one can see that the 30 metabolite markers from the NMR–MS data included 11 NMR 
variables and 19 MS variables. Most of the NMR (MS) variables selected by MCCV-BVE-
PLSDA from the NMR–MS data overlapped with those from the NMR (MS) data alone, 
while a number of important variables were unique to the different data sets.
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Polyps versus Healthy Controls
Although of great importance for preventing the development of CRC, the metabolic profiles 
of polyp patients and healthy controls have not been compared as often as those for CRC.68 
Differentiating polyp patients from healthy controls is a challenging problem, and diagnostic 
tests other than colonoscopy generally show poor performance. Using the approach 
described above, classification accuracies of 0.67 ± 0.08, 0.71 ± 0.07, and 0.74 ± 0.07 were 
achieved using the selected NMR (three variables), MS (six variables), and NMR–MS (13 
variables) data sets, respectively (see Figure 3c and Table 2). Again, the statistical 
performance of NMR–MS data was significantly better than that of NMR or MS data alone, 
and variable selection was successful in producing a subset of metabolites that provided the 
best classification accuracy. The MCCV results shown in Figure 3d indicate that the 
classification accuracy of true class models was clearly higher than that of random 
permutations, although the performance is not as good as it is for distinguishing CRC. Table 
S6 shows the 13 important variables (four from NMR and nine from MS) identified in the 
NMR–MS data for separating polyps and healthy controls. For example, the level of lipids 
[NMR (1.209–1.302 ppm)] was increased in polyp patient serum while the level of orotate 
(MS) was decreased.
Interestingly, a number of important metabolites overlapped in the pairwise comparisons 
among polyps, CRC, and controls (Tables S4–S6). For example, proline (NMR–MS data) 
was important in the comparisons of CRC versus controls (Table S4) and CRC versus polyps 
(Table S5). However, we did not observe a metabolite that was important in the NMR–MS 
data for all the three pairwise comparisons, although lactate was important in all the MS 
analyses alone, as indicated in Tables S4–S6. CRC had the lowest adenosine level (NMR–
MS data), and polyp patient serum had the highest level of adenosine. The level of orotate 
was increased in CRC compared to that in polyps, and it was decreased in polyps compared 
to controls, such that polyp patients had the lowest levels of orotate. The level of this 
metabolite (and a few others) did not continuously increase or decrease from controls to 
polyps, and then to CRC, which indicates that CRC disease progression, as reflected in 
metabolism, is likely a very complex process.
Figure 4 shows the results of MCCV-BVE-PLSDA, but based on AUROC to estimate the 
classification performance. These results confirmed that variable selection is highly useful 
for improving multivariate statistical analysis, and the combination of NMR and MS has a 
better diagnosis performance than NMR or MS alone. While AUROC and classification 
accuracy are highly correlated, they do not measure performance identically.
Metabolic Pathways
Although detailed biological analysis is beyond the scope of this paper, a number of 
metabolite changes in important metabolic pathways were observed in this study that are of 
potential significance to CRC and polyp and are consistent with those reported in previous 
studies.15,49–52 These pathways include glycolysis, the TCA cycle, fatty acid metabolism, 
amino acid metabolism, glutaminolysis, etc. In Figure 5, biomarker candidates discovered 
from the NMR–MS data are highlighted for the pairwise comparisons among CRC, polyps, 
and controls. Both NMR (red stars) and MS (blue circles) significantly contribute to the 
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altered metabolism shown in Figure 5, which should be helpful for improving our 
understanding of metabolite perturbations and the mechanisms related to CRC and polyp 
development.
In particular, glucose (detected by NMR) was found to be upregulated in CRC compared to 
controls (Table S4). This could be due to the need for cancer cells to take up glucose to 
maintain a high rate of glycolysis, which produces lactate even under aerobic conditions to 
fulfill the cells’ large demand for carbon substrates.10,69 In fact, some other glycolysis 
intermediates, such as PEP (MS) and pyruvate (MS), are also highlighted in Figure 5. 
Cancer cells also use glutamine as an important energy source (glutamine addiction or 
glutaminolysis),10,70 which explains the perturbed glutamine levels (MS) indicated in Figure 
5. Amino acid metabolism was significantly impacted by CRC and polyps, as well. For 
example, changes in alanine (MS), histidine (NMR and MS), aspartate (MS), etc., were 
emphasized in our statistical modeling. Alterations of amino acid levels can indicate the 
altered cancer cell activities, e.g., synthesis of proteins or catabolism to provide energy 
and/or other metabolite substrates. Fumarate (MS), citrate (NMR), and oxaloacetate (MS) 
are important metabolites in the TCA cycle, and their altered levels (Figure 5) fit well with 
the hypothesis that the TCA cycle is altered by CRC and polyp formation. Purine 
metabolism and fatty acid/lipid metabolism changes are also linked to CRC and polyps, 
based on the significant changes in the levels of adenosine (MS), lipids (NMR), and 
linolenic acid (MS). It is clear from Figure 5 that both NMR and MS are valuable methods 
for identifying metabolic changes that occur in patients with CRC and polyps.
Overall, both NMR and MS have advantages and disadvantages as predominant analytical 
methods in metabolomics, and their combination can make use of their strengths that include 
NMR’s reproducibility and quantitative nature, along with MS’s high sensitivity and broad 
coverage. In this study, considering the complementary analytical features of NMR and MS, 
we believe that leveraging both methods will provide new insights for biomarker discovery 
and disease diagnosis. Given the large number of detectable metabolites, we recommend 
using an appropriate variable selection step, such as MCCV-BVE-PLSDA, to extract a 
useful set of metabolite markers from both the NMR and MS data, instead of simply 
concatenating them together. This new approach can improve statistical performance and 
provide more comprehensive biological interpretation. While performing both NMR and MS 
experiments requires more effort and expense, on the basis of the examples provided in this 
study, we believe that the benefits outweigh the costs, especially at the biomarker discovery 
stage.
The aim of this study was not to determine the best variable selection method, but to 
demonstrate the importance of variable selection, especially in the case of combining NMR 
and MS data, which is infrequently investigated in metabolomics. MCCV-BVE-PLSDA in 
this study is an expansion of the BVE-PLSDA approach based on leave-one-out cross 
validation.58 Notably, MCCV-BVE-PLSDA is different from the methods based on a 
predefined variable ranking list,71,72 which may lead to filtering out a variable that performs 
poorly alone but becomes highly useful when combined with other variables. In each 
iteration of MCCV-BVE-PLSDA, each variable is combined with n – 2 other variables (n is 
the total number of variables in this iteration) in PLSDA modeling n – 1 times (each time a 
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different variable is excluded from our analysis). We remove the variable (one for each 
iteration) without which the remaining variables produce the highest prediction accuracy. In 
addition, we performed regression analysis with a number of previous variable selection 
methods.73–77 For example, Figure S3 shows the results of MCCV-BVE-hierarchical 
PLSDA, and Figure S4 shows the results of the variable importance in the projection (VIP)-
based stepwise selection method [MCCV-BVE-PLSDA (VIP) comparing healthy controls vs 
polyps]. All these results indicated that variable selection is very important in multivariate 
statistical analysis in picking a subset of variables that provide the best prediction accuracy. 
These results also show that the combination of NMR and MS exhibits a statistical 
performance better than that of NMR or MS alone. MCCV-BVE-PLSDA is thus a valuable 
and complementary approach to previous variation selection methods,73–77 especially for 
combining NMR and MS data, and provides a set of significant variables worth further 
investigation. MCCV-BVE-PLSDA is also straightforward, is easy to implement, and can 
identify the contribution of each individual variable to multivariate statistical models. 
Because of the limited number of samples, MCCV was used for internal cross validation in 
this study; however, it can be easily adapted to external cross validation when a larger 
number of samples is available. In addition, our data analysis approach is relatively universal 
and can be expanded to combine other analytical technologies.
CONCLUSIONS
In this study, we developed and applied the MCCV-BVE-PLSDA approach to examine the 
performance of combining NMR and MS for discovery metabolomics. We profiled serum 
metabolites from CRC patients, patients with polyps, and healthy controls, which were 
measured by NMR and LC/MS/MS. MCCV-BVE-PLSDA identified the subsets of 
metabolites with good diagnostic performance that could be initially validated using MCCV. 
Further validation will require more samples and would benefit from additional efforts to 
fully quantify the metabolite biomarkers and verify their robustness, which we are pursuing. 
Importantly, it was found that the combination of NMR and MS showed a statistical 
performance better than that of NMR or MS alone. Both NMR and MS contributed 
significantly to the achievement of a comprehensive biological interpretation for 
understanding CRC and polyp development mechanisms. Therefore, when possible, we 
recommend the combined use of NMR and MS along with appropriate variable selection 
methods in metabolomics, especially for the purpose of discovering biomarker candidates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flowchart indicating the steps for MCCV-BVE-PLSDA.
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Figure 2. 
(a) Correlation between all NMR and MS variables. (b) Correlation between the subset of 
metabolites (labeled in the figure) that can be detected by both NMR and MS. The X axis 
provides an index of all NMR variables in the data matrix, and the Y axis provides an index 
of all MS variables in the data matrix. The metabolites are listed in Tables S1 (NMR) and S3 
(MS, highlighted).
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Figure 3. 
(a) Results of MCCV-BVE-PLSDA for selecting a subset of variables to differentiate CRC 
from healthy controls, using NMR (solid red line), MS (dashed green line), and NMR–MS 
(dotted blue line) data. (b) Classification accuracy of true class (red dots) and random 
permutation (blue squares) models in MCCV, when the selected set of variables was used for 
MCCV-BVE-PLSDA modeling in panel a. (c) Results of MCCV-BVE-PLSDA for selecting 
a subset of variables to differentiate healthy controls from polyp patients, using NMR (solid 
red line), MS (dashed green line), and NMR–MS (dotted blue line) data. (d) Classification 
accuracy of true class (red dots) and random permutation (blue squares) models in MCCV, 
when the selected set of variables was used for MCCV-BVE-PLSDA modeling in panel c.
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Figure 4. 
Results of MCCV-BVE-PLSDA (AUROC) in selecting a subset of variables using the NMR 
(solid red line), MS (dashed green line), and NMR–MS (dotted blue line) data to compare 
(a) healthy controls vs CRC, (b) polyps vs CRC, and (c) healthy controls vs polyps. MCCV-
BVE-PLSDA (AUROC) is the same as MCCV-BVE-PLSDA but uses AUROC values to 
estimate the classification performance.
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Figure 5. 
Metabolism pathway diagram showing important metabolites in the NMR–MS data for the 
pairwise comparisons among CRC, polyps, and healthy controls. The NMR metabolites are 
highlighted with red stars; the MS metabolites are highlighted with blue circles.
Deng et al. Page 18
Anal Chem. Author manuscript; available in PMC 2017 May 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Deng et al. Page 19
Table 1
Summary of Demographic and Clinical Information of Subjects Recruited and Analyzed for This Study
healthy controls polyps CRC
no. of samples (no. of patients) 55 (55) 44 (44) 28 (28)
age, mean (range) 52.8 (21–74) 56.1 (39–68) 55.3 (27–86)
gender
 male 25 23 16
 female 30 21 12
no. of polyps
 0–5 – 26 –
 6–9 – 4 –
 10–15 – 3 –
 ≥16 – 11 –
cancer stage
 stage I/II – – 3
 stage III – – 8
 stage IV – – 17
diagnosis
 colon cancer – 19
 rectal cancer – 9
ethnicity
 Caucasian 50 23 15
 African American 4 1 2
 Asian 0 1 0
 NAa 1 19 11
a
Information not available.
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